• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 11-K filed by USANA Health Sciences Inc.

    6/12/26 8:15:59 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $USNA alert in real time by email
    usna-20260612
    00008962640000896264FALSEFALSEUsana Health Sciences, Inc.Usana Health Sciences, Inc.iso4217:USDutr:Yxbrli:pureusna:loanxbrli:sharesiso4217:USDxbrli:shares00008962642025-01-012025-12-310000896264usna:EBP001Member2025-01-012025-12-310000896264usna:EBP001Memberus-gaap:MutualFundMember2025-12-310000896264usna:EBP001Memberus-gaap:MutualFundMember2024-12-310000896264usna:EBP001Memberus-gaap-ebp:EmployeeBenefitPlanEmployerCommonStockFundMember2025-12-310000896264usna:EBP001Memberus-gaap-ebp:EmployeeBenefitPlanEmployerCommonStockFundMember2024-12-310000896264usna:EBP001Memberusna:CollectiveInvestmentFundMember2025-12-310000896264usna:EBP001Memberusna:CollectiveInvestmentFundMember2024-12-310000896264usna:EBP001Member2025-12-310000896264usna:EBP001Member2024-12-310000896264usna:EBP001Membersrt:MinimumMember2025-01-012025-12-310000896264usna:EBP001Membersrt:MaximumMember2025-01-012025-12-310000896264usna:EBP001Memberusna:EBPEmployerMatchingContributionMember2025-01-012025-12-310000896264usna:EBP001Memberusna:EBPNonElectiveEmployerContributionsMember2025-01-012025-12-310000896264usna:EBP001Memberus-gaap-ebp:EbpNonemployerCommonStockMember2025-12-310000896264usna:EBP001Memberus-gaap-ebp:EbpNonemployerCommonStockMember2024-12-310000896264usna:EBP001MemberMutual Funds | Fidelity® 500 Index Fund2025-12-310000896264usna:EBP001MemberMutual Funds | Fidelity® Large Cap Growth Index Fund2025-12-310000896264usna:EBP001MemberMutual Funds | American Funds 2050 Target Date Retirement Fund® Class R-62025-12-310000896264usna:EBP001MemberMutual Funds | American Funds 2045 Target Date Retirement Fund® Class R-62025-12-310000896264usna:EBP001MemberMutual Funds | American Funds 2040 Target Date Retirement Fund® Class R-62025-12-310000896264usna:EBP001MemberMutual Funds | MFS International Growth Fund Class R62025-12-310000896264usna:EBP001MemberMutual Funds | American Funds 2035 Target Date Retirement Fund® Class R-62025-12-310000896264usna:EBP001MemberMutual Funds | American Funds 2055 Target Date Retirement Fund® Class R-62025-12-310000896264usna:EBP001MemberMutual Funds | American Funds 2030 Target Date Retirement Fund® Class R-62025-12-310000896264usna:EBP001MemberMutual Funds | PGIM Total Return Bond Fund Class R-62025-12-310000896264usna:EBP001MemberMutual Funds | American Funds American Balanced Fund® Class R-62025-12-310000896264usna:EBP001MemberMutual Funds | American Funds 2060 Target Date Retirement Fund® Class R-62025-12-310000896264usna:EBP001MemberMutual Funds | Fidelity® Mid Cap Index Fund2025-12-310000896264usna:EBP001MemberMutual Funds | Fidelity® Small Cap Index Fund2025-12-310000896264usna:EBP001MemberMutual Funds | American Funds New World Fund® Class R-62025-12-310000896264usna:EBP001MemberMutual Funds | Carillon Eagle Mid Cap Growth Fund Class R-62025-12-310000896264usna:EBP001MemberMutual Funds | Janus Henderson Triton Fund Class I2025-12-310000896264usna:EBP001MemberMutual Funds | Victory Sycamore Established Value Fund Class R-62025-12-310000896264usna:EBP001MemberMutual Funds | Fidelity® Total International Index Fund2025-12-310000896264usna:EBP001MemberMutual Funds | American Funds 2025 Target Date Retirement Income Fund Class R-62025-12-310000896264usna:EBP001MemberMutual Funds | Principal Real Estate Securities Fund Institutional Class2025-12-310000896264usna:EBP001MemberMutual Funds | Undiscovered Managers Behavioral Value Fund Class L2025-12-310000896264usna:EBP001MemberMutual Funds | American Funds 2020 Target Date Retirement Fund® Class R-62025-12-310000896264usna:EBP001MemberMutual Funds | PIMCO Income Fund Institutional Class2025-12-310000896264usna:EBP001MemberMutual Funds | Fidelity® Government Money Market Fund2025-12-310000896264usna:EBP001MemberMutual Funds | American Funds 2010 Target Date Retirement Fund® Class R-62025-12-310000896264usna:EBP001MemberMutual Funds | American Funds 2015 Target Date Retirement Income Fund Class R-62025-12-310000896264usna:EBP001MemberUSANA Health Sciences, Inc. Stock Fund2025-12-310000896264usna:EBP001MemberCollective Investment Fund | Galliard Stable Return Fund C2025-12-31


     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     


    FORM 11-K
     

     
    ☒ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

    For the fiscal year ended December 31, 2025 

    or
     
    ☐TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
     For the transition period from ___________ to ____________
     
    Commission file number: 001-35024
     
     
     
    A. Full title of the plan and the address of the plan, if different from that of the issuer named below:
     
    USANA HEALTH SCIENCES 401(k) PLAN
     
     
    B. Name of issuer of the securities held pursuant to the plan and the address of its principal executive office:
     
    USANA HEALTH SCIENCES, INC.
    3838 West Parkway Blvd.
    Salt Lake City, Utah 84120

     





     
     
    USANA HEALTH SCIENCES 401(k) PLAN
    FORM 11-K
    For the Year Ended December 31, 2025

    INDEX

     Page
      
    Report of Independent Registered Public Accounting Firm
    1
    Financial Statements:
     
    Statements of Net Assets Available for Benefits
    2
    Statement of Changes in Net Assets Available for Benefits
    3
    Notes to Financial Statements
    4
    Schedule of Assets (Held at End of Year)*
    8
    Exhibit
    9
    Signature
    10


    * Other supplementary schedules required by section 2520.103-10 of the Department of Labor’s Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974 have been omitted because they are not applicable.






    REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM


    To the Plan Administrators and Plan Participants of
    USANA Health Sciences 401(k) Plan

    Opinion on the Financial Statements
    We have audited the accompanying statements of net assets available for benefits of the USANA Health Sciences 401(k) Plan (the Plan) as of December 31, 2025 and 2024, and the related statement of changes in net assets available for benefits for the year ended December 31, 2025, and the related notes to financial statements (collectively referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the net assets available for benefits of the Plan as of December 31, 2025 and 2024, and the changes in net assets available for benefits for the year ended December 31, 2025, in conformity with accounting principles generally accepted in the United States of America.

    Basis for Opinion
    These financial statements are the responsibility of the Plan’s management. Our responsibility is to express an opinion on the Plan’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Plan in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

    We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Plan is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Plan’s internal control over financial reporting. Accordingly, we express no such opinion.

    Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

    Supplemental Information
    The supplemental information contained in the schedule of assets (held at end of year) has been subjected to audit procedures performed in conjunction with the audit of the Plan's financial statements. The supplemental information is the responsibility of the Plan's management. Our audit procedures included determining whether the supplemental information reconciles to the financial statements or the underlying accounting and other records, as applicable, and performing procedures to test the completeness and accuracy of the information presented in the supplemental information. In forming our opinion on the supplemental information, we evaluated whether the supplemental information, including its form and content, is presented in conformity with the Department of Labor's Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974. In our opinion, the supplemental information is fairly stated, in all material respects, in relation to the financial statements as a whole.

    /s/ Tanner LLP


    We have served as the Plan’s auditor since 2004.

    Salt Lake City, Utah
    June 12, 2026
        

    1



    USANA HEALTH SCIENCES 401(k) PLAN
    Statements of Net Assets Available for Benefits


    December 31,
    20252024
    Assets:
    Investments, at fair value:
    Mutual funds$127,589,410 $115,197,895 
    USANA Health Sciences, Inc. Stock Fund1,318,480 2,462,308 
    Collective investment fund7,305,763 6,264,482 
    Total investments136,213,653 123,924,685 
    Receivables:
    Notes receivable from participants2,284,606 2,400,566 
    Total receivables2,284,606 2,400,566 
    Net assets available for benefits$138,498,259 $126,325,251 

    The accompanying notes are an integral part of these statements.

    2


    USANA HEALTH SCIENCES 401(k) PLAN
    Statement of Changes in Net Assets Available for Benefits
    Year Ended December 31, 2025


    Additions:
    Investment income:
    Net appreciation in fair value of investments$13,029,921 
    Interest and dividends5,735,711 
    Investment income18,765,632 
    Interest on notes receivable from participants188,179 
    Contributions:
    Participants6,300,713 
    Employer2,312,143 
    Rollovers1,163,133 
    Total contributions9,775,989 
    Total additions28,729,800 
    Deductions:
    Benefits paid to participants(16,338,676)
    Administrative expenses(218,116)
    Total deductions(16,556,792)
    Increase in net assets available for benefits12,173,008 
    Net assets available for benefits:
    Beginning of the year126,325,251 
    End of the year$138,498,259 

    The accompanying notes are an integral part of these statements.
    3


    USANA HEALTH SCIENCES 401(k) PLAN
    NOTES TO FINANCIAL STATEMENTS
     
    NOTE A – DESCRIPTION OF THE PLAN

    The following description of the USANA Health Sciences 401(k) Plan (the “Plan”) provides only general information. Participants and other financial statement users should refer to the Plan document, as amended, and summary plan description for a more complete description of the Plan’s provisions.

    1.General

    The Plan is a defined contribution plan covering substantially all United States non-union employees of USANA Health Sciences, Inc. (collectively, the “Company” or the “Employer”) who have completed one month of service and are age 18 or older. The Plan is subject to the provisions of the Employee Retirement Income Security Act of 1974 (“ERISA”), as amended, and permits traditional 401(k) deferrals (pre-tax) as well as Roth 401(k) deferrals (after-tax). 

    The trustee for the 2025 and 2024 Plan years is Fidelity Management Trust Company (“Fidelity” or “Trustee”) and the recordkeeping functions were performed by Fidelity Workplace Services, LLC.

    On December 29, 2022, the Setting Every Community Up for Retirement Enhancement Act 2.0 ("SECURE 2.0") was signed into law, continuing the themes and reforms that began with the 2019 CARES Act. Many of the provisions of SECURE 2.0 became effective in 2024, including mandatory and optional provisions impacting defined contribution plans. The Plan has adopted all of the applicable mandatory provisions, including increasing the age at which required minimum distributions start, eliminating the required minimum distributions for Roth 401(k) accounts, and new spousal beneficiary rules.

    2.Contributions

    Each year participants may elect to contribute up to 75 percent of their annual compensation subject to certain limits as defined in the Plan. Participant contributions are limited by the Internal Revenue Code, which established a maximum contribution of $23,500 ($31,000 for participants age 50 or older and $34,750 for participants age 60 through 63 during 2025) for the year ended December 31, 2025. Participants may elect to make pre-tax contributions and/or after-tax elective contributions into their accounts. Participants may also contribute rollover amounts representing distributions from certain other defined benefit or defined contribution plans. Under the safe harbor and certain other provisions of the Plan, eligible employees who have not made an affirmative election to defer or not defer will have deferrals withheld in the amount of 6 percent of their compensation, to be invested in the appropriate target date retirement fund. Participants may direct their investments into one or more of the investment options offered by the Plan, with no more than 25 percent of their investment allocations directed into shares of the USANA Health Sciences, Inc. Stock Fund (“Stock Fund”).

    The Company provides a matching contribution equal to 100 percent of the first 1 percent of a participant’s compensation that is contributed as an elective deferral by the participant, and 50 percent of elective deferrals between one and 6 percent of the participant’s compensation. The Company’s Board of Directors may also authorize additional contributions to the Plan. No additional contributions were authorized during the year ended December 31, 2025.

    3.Participant accounts

    Self-directed individual investment accounts are maintained for each Plan participant. Each participant’s account is adjusted for the participant’s contributions and allocations of (a) the Company’s contributions, (b) investment gains or losses, (c) interest and dividends, and (d) administrative expenses. The allocation of the Company’s discretionary contributions and forfeitures is based on each participant’s contribution, as defined by the Plan. The benefit to which a participant is entitled is the benefit that can be provided from the participant’s vested account.

    4.Vesting

    Participants are fully vested in their voluntary contributions, including any net investment income on those contributions. The Company’s matching contributions fully vest at the end of two years of service. Non-elective employer contributions vest 25% at the end of each year and are fully vested after four years of service. 

    4


    5.Notes receivable from participants

    A participant may borrow a minimum of $1,000 through up to a maximum of three loans, that in the aggregate are equal to the lesser of $50,000 or 50 percent of his or her vested account balance. Loans are secured by the balances in the participants’ accounts and bear interest at rates ranging from 4.25 percent to 9.50 percent, which rates were commensurate with prevailing rates at the time of loan origination. Principal and interest are paid ratably through payroll deductions. Loans are re-paid over a five-year period, unless the loans were used to purchase a principal residence, in which case the payback period may not exceed 30 years. As of December 31, 2025, the Plan had outstanding loans to participants with maturities ranging from 2026 through 2054.

    6.Benefits paid to participants

    On termination of service due to death, permanent disability, or retirement, a participant or beneficiary may receive a lump-sum amount equal to the value of the participant’s vested interest in his or her account. For termination of service due to other reasons, the Plan will automatically make a lump-sum distribution of the value of the participant’s vested interest in his or her account where the account balance is less than $7,000. Hardship withdrawals are allowed for participants incurring a “specific and heavy financial need,” as defined by the Plan. Hardship withdrawals are strictly regulated under the Internal Revenue Code and the regulations thereunder, and a participant must exhaust all available loan options and available distributions prior to requesting a hardship withdrawal.

    7.Forfeited accounts

    Forfeited accounts related to the Company’s matching contributions may be used to pay any administrative expenses or used to reduce any future Employer matching contributions. The table below provides a reconciliation of the balance of forfeited accounts as of and for the year ended December 31, 2025.

     
    Balance as of December 31, 2024$174,187 
    Forfeitures65,840 
    Employer matching contributions(172,468)
    Earnings on forfeited account balance3,997 
    Administrative expenses(42,087)
    Balance as of December 31, 2025$29,469 

    During the year ended December 31, 2025, $172,468 of forfeitures were used to reduce Employer matching contributions and $42,087 forfeitures were used to pay administrative expenses.

    8.Expenses

    The Company, as the Plan Sponsor, pays certain administrative expenses of the Plan. The expenses paid by Plan participants or from the forfeiture account totaled $218,116, which are reflected on the Statement of Changes in Net Assets Available for Benefits for the year ended December 31, 2025.

    NOTE B – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

    1.Basis of accounting

    The financial statements of the Plan are presented using the accrual method of accounting in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).

    2.Use of estimates

    The preparation of financial statements in conformity with U.S. GAAP requires Plan management to make estimates and assumptions that affect certain reported amounts of net assets available for benefits at the date of the financial statements, the changes in net assets available for benefits during the reporting period and, when applicable, the disclosure of contingent assets and liabilities at the date of the financial statements. Key estimates include determination of the fair value of investments. Actual results may differ from estimates and assumptions made.
    5



    3.Investment valuation and income recognition

    The Plan’s investments are stated at fair value. Quoted market prices are used to value investments in shares of mutual funds and the Stock Fund. Units of the collective investment fund are valued at net asset value, which approximates fair value, using daily market information. Net appreciation (depreciation) caused by fluctuations in the value of investments is reflected in the statement of changes in net assets available for benefits. Amounts invested may earn interest and dividends, which in turn are reinvested.

    Purchases and sales of securities are recorded on a trade-date basis. Income from interest is recorded on the accrual basis. Dividends are recorded on the ex-dividend date. Earnings and losses within each fund are allocated to participants based on their proportionate shares in the fund.

    In general, the Plan’s securities are exposed to various risks, such as interest rate, credit, and overall market volatility. Due to the level of risk associated with certain investment securities, it is reasonably possible that changes in the values of investment securities will occur in the near term and that such changes could materially affect the amounts reported in the accompanying statements of net assets available for benefits.

    4.Notes receivable from participants

    Notes receivable from participants represent participant loans and are valued at their unpaid principal balance plus any accrued but unpaid interest, which approximates fair value. As of December 31, 2025 and December 31, 2024, no allowances for credit losses had been recorded. If a participant ceases to make loan repayments and the Plan Administrators deem the note receivable from a participant to be a distribution, the note receivable balance is reduced and a benefit payment is recorded.

    5.Benefits paid to participants

    Benefits are recorded when paid. As of December 31, 2025 and December 31, 2024, there were no distributions that had been requested but not paid.

    6.Subsequent events

    Plan management has evaluated events occurring subsequent to year-end through June 12, 2026, which is the date the financial statements were available to be issued.

    NOTE C – FAIR VALUE MEASUREMENTS

    The Plan reports investments in accordance with established authoritative guidance, which requires a three-level valuation hierarchy for disclosure of fair value measurements. The valuation hierarchy is based upon the transparency of inputs to the valuation of an asset or liability as of the measurement date.

    The three levels are defined as follows:

    ●Level 1 inputs are quoted market prices in active markets for identical assets or liabilities that are accessible at the measurement date.

    ●Level 2 inputs are from other than quoted market prices included in Level 1 that are observable for the asset or liability, either directly or indirectly.

    ●Level 3 inputs are unobservable and are used to measure fair value in situations where there is little, if any, market activity for the asset or liability at the measurement date.

    Mutual funds are valued at the total market value of the underlying assets based upon the publicly quoted price of each fund multiplied by the respective number of units held as of the measurement date and are classified as Level 1 investments.

    The Stock Fund is a unitized stock fund consisting primarily of the Company’s common stock, and cash for daily liquidity purposes. The Stock Fund is classified as Level 1, as the total fair value is equal to the quoted market value of total common stock plus the carrying amount of cash, which approximates fair value. The cash balance held by the Plan was $1,038 and $1,068 as of December 31, 2025 and December 31, 2024, respectively.

    6


    In accordance with Subtopic 820-10, the collective investment fund is measured using the net asset value per unit as a practical expedient and is therefore not classified in the fair value hierarchy.

    Redemption frequency for the collective investment fund is immediate, contains no unfunded commitments, and has no redemption restrictions.

    NOTE D – EXEMPT PARTY-IN-INTEREST TRANSACTIONS

    Plan assets include common stock of the Company. Transactions with respect to shares of the Company’s common stock qualify as party-in-interest transactions. As of December 31, 2025 and December 31, 2024, the Plan held 67,114 shares of the Company’s common stock in the Stock Fund with a value of $19.63 per share, and 68,577 shares of the Company’s common stock in the Stock Fund with a value of $35.89 per share, respectively.

    Notes receivable from participants as of December 31, 2025 and December 31, 2024, were $2,284,606 and $2,400,566, respectively. Notes receivable are considered party-in-interest transactions. Interest income pertaining to notes receivable from participants totaled $188,179 for 2025.

    Certain Plan investments are shares in registered investment company funds managed by Fidelity Investments, an affiliate of the Trustee as defined by the Plan, and therefore, these transactions qualify as party-in-interest transactions.

    NOTE E – PLAN TERMINATION

    Although it has not expressed any intent to do so, the Company has the right under the Plan to discontinue the Company’s contributions at any time and to terminate the Plan subject to the provisions of ERISA. In the event of Plan termination, participants become 100 percent vested in their accounts.

    NOTE F – TAX STATUS

    The Plan has adopted a non-standardized prototype plan for which the Internal Revenue Service (“IRS”) has issued a favorable opinion letter covering the qualification of the Plan. The Plan Administrators and the Plan’s tax counsel do not anticipate that changes in the Plan after the date of the IRS opinion letter will affect the qualified and tax-exempt status of the Plan. Accordingly, the financial statements of the Plan do not include provisions, assets or liabilities related to income taxes.

    U.S. GAAP requires management to evaluate income tax positions taken by the Plan and to recognize an income tax liability if the Plan has taken an uncertain tax position that more likely than not would not be sustained upon examination by taxing authorities. The Plan Administrators analyzed the tax positions taken by the Plan and have concluded that as of December 31, 2025 and December 31, 2024, there are no uncertain tax positions taken or expected to be taken that would require recognition of a liability (or asset) or disclosure in the financial statements. The Plan is subject to routine audits by tax jurisdictions for tax years for which the applicable statutes of limitations have not expired; however, there are currently no audits for any tax periods in progress.

    7


    USANA HEALTH SCIENCES 401(k) PLAN
    SUPPLEMENTAL INFORMATION
    Employer Identification Number: 87-0500306
    Plan Number: 001
    SCHEDULE H, PART IV, Line 4(i)
    SCHEDULE OF ASSETS (HELD AT END OF YEAR)
    As of December 31, 2025
    ( a )( b )( c )( d )( e )
    IDENTITY OF ISSUE, BORROWER, LESSOR, OR SIMILAR PARTYDESCRIPTION OF INVESTMENTCOSTCURRENT VALUE
    *Fidelity® 500 Index FundMutual funds**$25,598,120 
    *Fidelity® Large Cap Growth Index FundMutual funds**14,134,252 
    American Funds 2050 Target Date Retirement Fund® Class R-6Mutual funds**13,955,883 
    American Funds 2045 Target Date Retirement Fund® Class R-6Mutual funds**9,550,146 
    American Funds 2040 Target Date Retirement Fund® Class R-6Mutual funds**9,459,226 
    MFS International Growth Fund Class R6Mutual funds**6,920,441 
    American Funds 2035 Target Date Retirement Fund® Class R-6Mutual funds**6,842,221 
    American Funds 2055 Target Date Retirement Fund® Class R-6Mutual funds**6,777,291 
    American Funds 2030 Target Date Retirement Fund® Class R-6Mutual funds**5,459,873 
    PGIM Total Return Bond Fund Class R-6Mutual funds**4,764,323 
    American Funds American Balanced Fund® Class R-6Mutual funds**4,251,315 
    American Funds 2060 Target Date Retirement Fund® Class R-6Mutual funds**2,958,204 
    *Fidelity® Mid Cap Index FundMutual funds**2,851,989 
    *Fidelity® Small Cap Index FundMutual funds**2,643,309 
    American Funds New World Fund® Class R-6Mutual funds**2,153,135 
    Carillon Eagle Mid Cap Growth Fund Class R-6Mutual funds**1,850,842 
    Janus Henderson Triton Fund Class IMutual funds**1,402,735 
    Victory Sycamore Established Value Fund Class R-6Mutual funds**1,398,089 
    *Fidelity® Total International Index FundMutual funds**1,158,748 
    American Funds 2025 Target Date Retirement Income Fund Class R-6Mutual funds**1,119,518 
    Principal Real Estate Securities Fund Institutional ClassMutual funds**1,026,002 
    Undiscovered Managers Behavioral Value Fund Class LMutual funds**988,232 
    American Funds 2020 Target Date Retirement Fund® Class R-6Mutual funds**253,741 
    PIMCO Income Fund Institutional ClassMutual funds**30,534 
    *Fidelity® Government Money Market FundMutual funds**21,217 
    American Funds 2010 Target Date Retirement Fund® Class R-6Mutual funds**11,067 
    American Funds 2015 Target Date Retirement Income Fund Class R-6Mutual funds**8,957 
    127,589,410 
    *USANA Health Sciences, Inc. Stock FundStock Fund**1,318,480 
    Galliard Stable Return Fund CCollective investment fund**7,305,763 
    *Notes receivable from participants
    Loans with interest rates ranging from 4.25% to 9.50%, with maturities through 2054
    N/A2,284,606 
    $138,498,259 
    *Party-in-interest
    **Column (d) cost information is not presented as these investments are participant directed.
    See accompanying Report of Independent Registered Public Accounting Firm.
     
    8


    EXHIBIT

    Exhibit
    Number
     Description
    23.1 
    Consent of Independent Registered Public Accounting Firm (filed herewith)
    9


    SIGNATURE

    The Plan. Pursuant to the requirements of the Securities Exchange Act of 1934, the trustees (or other persons who administer the employee benefit plan) have duly caused this annual report to be signed on its behalf by the undersigned hereunto duly authorized.

    Date:
    June 12, 2026
     
     
     
      
     USANA Health Sciences 401(k) Plan
      
     /s/ G. Douglas Hekking
     G. Douglas Hekking
     
    Chief Financial Officer
    (Principal Financial and Accounting Officer)
    Plan Sponsor
     
     
    10
    Get the next $USNA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $USNA

    DatePrice TargetRatingAnalyst
    6/23/2023Buy
    Sidoti
    7/7/2022$78.00 → $53.00Hold → Underperform
    Jefferies
    4/14/2022$86.00Neutral
    DA Davidson
    More analyst ratings

    $USNA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    USANA Celebrates 10 Years of Making the World a Better Place During World Service Week

    SALT LAKE CITY, June 16, 2026 /PRNewswire/ -- For the past 10 years, the USANA community comes together every June through acts of service during World Service Week led by the USANA Foundation. World Service Week unites the USANA family across continents for a week of service and compassion. Volunteers, Brand Partners, employees, and their families uplift vulnerable families, support local organizations, and share hope through meaningful acts of kindness. For World Service Week this year, USANA is encouraging Brand Partners to add $10 or whatever they can give to their Subscribe & Save orders. These donations will help USANA re

    6/16/26 7:22:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    USANA's Celavive Contouring Face & Neck Crème Named Among Canada's Top Skincare Products

    TORONTO, June 8, 2026 /CNW/ -- USANA Health Sciences, Inc., a global leader in cellular nutrition, announced today that its Celavive Contouring Face & Neck Crème has earned top recognition from The Beauty Awards Canada as one of the best skincare products in the country. The Contouring Face & Neck Crème won in the Best Neck & Décolleté Cream category. "Recognition from The Beauty Awards Canada is a significant achievement for our Celavive skincare line," said Brent Neidig, USANA's chief commercial officer. "The Contouring Face & Neck Crème was developed to deliver a luxurious skincare experience backed by innovative science, an

    6/8/26 6:46:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    USANA Earns Dual Best of State Honors for Product Innovation and Development

    USANA's CellSentials and Research and Development team honored at the awardsSALT LAKE CITY, June 4, 2026 /PRNewswire/ -- USANA, a leader in global nutrition, earned two Best of State awards in Salt Lake City, Utah, recognizing its CellSentials supplements and Research and Development team. USANA took home two Best of State medals this year in the following categories:Dietary Supplement—USANA CellSentials took home this honor for the tenth consecutive year Research and Development—USANA's R&D team won for the eighth timeTo learn more about USANA and its award-winning products, please visit USANA.com. "We are beyond honored to re

    6/4/26 6:47:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $USNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF COMMERCIAL OFFICER Neidig Brent sold $97,304 worth of shares (5,002 units at $19.45), closing all direct ownership in the company (SEC Form 4)

    4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)

    6/18/26 12:14:04 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    CHIEF COMMERCIAL OFFICER Neidig Brent sold $50,465 worth of shares (2,511 units at $20.10), decreasing direct ownership by 33% to 5,002 units (SEC Form 4)

    4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)

    6/16/26 3:42:03 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    CHIEF PEOPLE OFFICER Jones Paul A. sold $102,878 worth of shares (5,561 units at $18.50), closing all direct ownership in the company (SEC Form 4)

    4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)

    6/8/26 6:10:52 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $USNA
    SEC Filings

    View All

    $USNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    SEC Form 11-K filed by USANA Health Sciences Inc.

    11-K - USANA HEALTH SCIENCES INC (0000896264) (Filer)

    6/12/26 8:15:59 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    USANA Health Sciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - USANA HEALTH SCIENCES INC (0000896264) (Filer)

    5/20/26 4:24:08 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-Q filed by USANA Health Sciences Inc.

    10-Q - USANA HEALTH SCIENCES INC (0000896264) (Filer)

    5/12/26 4:35:39 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    Sidoti initiated coverage on USANA

    Sidoti initiated coverage of USANA with a rating of Buy

    6/23/23 9:12:38 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    USANA downgraded by Jefferies with a new price target

    Jefferies downgraded USANA from Hold to Underperform and set a new price target of $53.00 from $78.00 previously

    7/7/22 9:35:48 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    DA Davidson initiated coverage on USANA with a new price target

    DA Davidson initiated coverage of USANA with a rating of Neutral and set a new price target of $86.00

    4/14/22 7:45:27 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $USNA
    Leadership Updates

    Live Leadership Updates

    View All

    Kevin Guest Returns to USANA Health Sciences as CEO

    USANA Health Sciences, Inc. (NYSE:USNA) announced today a leadership transition as part of the Company's ongoing commitment to accelerating growth and enhancing shareholder value. Kevin Guest is returning to lead the Company as Chief Executive Officer, effective immediately. Mr. Guest, who has spent more than three decades at the Company, including eight years as CEO and the last three years as Executive Chairman, has agreed to again serve as USANA's CEO and will continue serving as Chairman. Mr. Guest succeeds Jim Brown, who has stepped down from his position of CEO and President. "We thank Jim for his contributions and his leadership over the past 19 years and in his role as CEO over th

    1/8/26 9:00:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    Solstice Advance Materials and Qnity Electronics Set to Join S&P 500; Others to Join S&P SmallCap 600

    NEW YORK, Oct. 27, 2025 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P SmallCap 600: Solstice Advance Materials Inc. (NASD: SOLS) will replace CarMax Inc. (NYSE:KMX) in the S&P 500, and CarMax will replace USANA Health Sciences Inc. (NYSE:USNA) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, October 31. S&P 500 and 100 constituent Honeywell International Inc. (NASD: HON) is spinning off Solstice Advance Materials in a transaction expected to be completed on October 30. Post spin-off, Honeywell International will remain in the S&P 500 and 100. CarMax and USANA Health Sciences no longer represent the large cap and small c

    10/27/25 6:10:00 PM ET
    $CAL
    $DD
    $EMN
    Shoe Manufacturing
    Consumer Discretionary
    Major Chemicals
    Industrials

    USANA Exec. Chairman Kevin Guest Celebrates Guitar Month, Stress Awareness Month for Harmony

    SALT LAKE CITY, April 1, 2025 /PRNewswire/ -- USANA Health Sciences (NYSE:USNA) Executive Chairman Kevin Guest marks April's convergence of International Guitar Month and Stress Awareness Month, as a perfect pairing that celebrates the healing power of music for mental well-being. While music has long been heralded as a universal remedy, the guitar offers far more than just melodies. Studies, stories and specialists alike agree: playing the guitar is a proven method to reduce stress. A passionate, performing guitarist himself, Guest invites others to join the cause. "Music has

    4/1/25 7:47:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $USNA
    Financials

    Live finance-specific insights

    View All

    USANA Health Sciences Reports First Quarter 2026 Results

    Company Continues to Make Significant Progress on Transformation to Becoming a Leading Omnichannel Health and Wellness Platform USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal first quarter ended April 4, 2026. Key Financial Results First Quarter 2026 vs. First Quarter 2025 Net sales of $250 million versus $250 million. Net earnings of $7.5 million versus $9.4 million. Diluted EPS of $0.41 as compared with $0.49. Adjusted diluted EPS(1) of $0.61 as compared with $0.73. Adjusted EBITDA(2) of $28.4 million versus $29.8 million. Core Nutritional Active Customers of 404,000 versus 459,000. Hiya Active Monthly Subscribers of 186

    5/5/26 4:15:00 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    USANA Schedules First Quarter 2026 Earnings Release and Conference Call

    USANA Health Sciences, Inc. (NYSE:USNA) today announced that first quarter 2026 results will be released after the close of market on Tuesday, May 5, 2026. Shortly following the issuance of the Company's earnings release, the Company will post its Management Commentary document on the Company's Investor Relations website (http://ir.usana.com) under the News/Events section. USANA will hold a conference call to discuss this announcement with analysts and institutional investors the following morning, Wednesday, May 6, 2026 at 11:00 a.m. Eastern Time. The call will be broadcast over the Internet and can be accessed at http://ir.usana.com. About USANA USANA develops and manufactures high-

    4/15/26 7:00:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    Next-Generation Platforms Scale Across Energy, Wellness, and Smokeless Consumer Segments

    Issued on behalf of Doseology Sciences Inc.Equity-Insider.com VANCOUVER, BC, March 5, 2026 /CNW/ -- Consumers are voting with their wallets, and zero-sugar is winning. Zero-sugar beverages are driving 6x more dollar growth than regular varieties as buyers actively choose clean-label products with natural sweeteners and functional ingredients[1]. The global market is forecast to expand from $350 billion in 2024 toward $500 billion by 2029, fueled by health-conscious consumers who want naturally functional products without heavy processing[1]. This structural shift is creating validated demand for precision-dosed, portable formats across energy and wellness categories, positioning Doseology Sc

    3/5/26 9:00:00 AM ET
    $HLF
    $NHTC
    $NMTC
    Other Pharmaceuticals
    Health Care
    Consumer Specialties
    Consumer Discretionary

    $USNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by USANA Health Sciences Inc. (Amendment)

    SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)

    2/13/24 10:49:58 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by USANA Health Sciences Inc. (Amendment)

    SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)

    2/13/23 11:26:45 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by USANA Health Sciences Inc. (Amendment)

    SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)

    2/11/22 3:48:24 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care